Escherichia coli resistant to Nitrofurantoin. Nitrofurans.
Nitrofurantoin was first synthesized in 1947 by scientists at the pharmaceutical company, Winthrop Chemical Company (now part of Sanofi). It was introduced to the market in 1953 and quickly became a go-to treatment for UTIs due to its effectiveness and relatively low risk of developing bacterial resistance. The drug is especially effective against Escherichia coli (E. coli), a common cause of UTIs. Over the decades, it has remained an important therapeutic option, though it's not typically used for infections outside the urinary tract due to its limited tissue distribution.
Nitrofurantoin was first synthesized in 1947 by scientists at the pharmaceutical company, Winthrop Chemical Company (now part of Sanofi). It was introduced to the market in 1953 and quickly became a go-to treatment for UTIs due to its effectiveness and relatively low risk of developing bacterial resistance. The drug is especially effective against Escherichia coli (E. coli), a common cause of UTIs. Over the decades, it has remained an important therapeutic option, though it's not typically used for infections outside the urinary tract due to its limited tissue distribution.
| AMP | Ampicillin | AMC | Amoxicillin/Clavulanate | CXM | Cefuroxime | SXT | Trimethoprim-Sulfamethoxazole |
| CIP | Ciprofloxacin | FOS | Fosfomycin | NFE | Nitrofurantoin |